Similar Items: Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2
- Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia
- Aging Is a Key Driver for Adult Acute Myeloid Leukemia
- Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance
- TNFAIP3 Reprograms T Cell Exhaustion and Restores Anti-Leukemia Immunity in Acute Myeloid Leukemia
- Prognostic Impact of European LeukemiaNet Genetic Risk Stratification System in Adult Patients With Acute Myeloid Leukemia
- Clinical implications of variant allele frequencies of genes in patients with acute myeloid leukemia